174 related articles for article (PubMed ID: 32743504)
1. Subcutaneous abatacept in rheumatoid arthritis: A real-life experience.
Sarmiento-Monroy JC; Parada-Arias L; Rodríguez-López M; Rodríguez-Jiménez M; Molano-González N; Rojas-Villarraga A; Mantilla RD
J Transl Autoimmun; 2019 Dec; 2():100016. PubMed ID: 32743504
[TBL] [Abstract][Full Text] [Related]
2. Association Between Baseline Anti-cyclic Citrullinated Peptide Antibodies and 6-Month Clinical Response Following Abatacept or TNF Inhibitor Treatment: A Real-World Analysis of Biologic-Experienced Patients with RA.
Harrold LR; Bryson J; Lehman T; Zhuo J; Gao S; Han X; Schrader A; Rebello S; Pappas DA; Sommers T; Kremer JM
Rheumatol Ther; 2021 Jun; 8(2):937-953. PubMed ID: 34047953
[TBL] [Abstract][Full Text] [Related]
3. Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control.
Dinis VG; Viana VT; Leon EP; Silva CA; Saad CG; Moraes JC; Bonfa ES; Medeiros-Ribeiro AC
Clin Rheumatol; 2020 Jun; 39(6):1747-1755. PubMed ID: 31927715
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.
Genovese MC; Tena CP; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Delaet I; Teng J; Alten R
J Rheumatol; 2014 Apr; 41(4):629-39. PubMed ID: 24584926
[TBL] [Abstract][Full Text] [Related]
5. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus.
Alten R; Tony HP; Bannert B; Nüßlein H; Rauch C; Connolly SE; Chartier M; Lozenski K; Hackl R; Forster A; Peichl P
Clin Rheumatol; 2023 Sep; 42(9):2321-2334. PubMed ID: 37314665
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
[TBL] [Abstract][Full Text] [Related]
8. Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort.
Molteni E; Pirone C; Ceccarelli F; Castellani C; Alessandri C; Di Franco M; Riccieri V; Spinelli FR; Priori R; Scrivo R; Conti F
Reumatismo; 2024 Jun; 76(2):. PubMed ID: 38916170
[TBL] [Abstract][Full Text] [Related]
9. Real-World Sarilumab Use and Rule Testing to Predict Treatment Response in Patients with Rheumatoid Arthritis: Findings from the RISE Registry.
Curtis JR; Yun H; Chen L; Ford SS; van Hoogstraten H; Fiore S; Ford K; Praestgaard A; Rehberg M; Choy E
Rheumatol Ther; 2023 Aug; 10(4):1055-1072. PubMed ID: 37349636
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of abatacept treatment: results of 12 months observation.
Borisova MA; Lukina GV; Sigidin YA; Aronova ES; Luchihina EL; Karateev DE; Glukhova SV; Nasonov EL
Ter Arkh; 2018 May; 90(5):44-49. PubMed ID: 30701888
[TBL] [Abstract][Full Text] [Related]
11. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.
Gottenberg JE; Courvoisier DS; Hernandez MV; Iannone F; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Finckh A
Arthritis Rheumatol; 2016 Jun; 68(6):1346-52. PubMed ID: 26815727
[TBL] [Abstract][Full Text] [Related]
12. Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.
Genovese MC; Pacheco-Tena C; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente RM; Nash P; Simon-Campos JA; Box J; Legerton CW; Nasonov E; Durez P; Elegbe A; Wong R; Li X; Banerjee S; Alten R
J Rheumatol; 2018 Aug; 45(8):1085-1092. PubMed ID: 29657147
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
Genovese MC; Covarrubias A; Leon G; Mysler E; Keiserman M; Valente R; Nash P; Simon-Campos JA; Porawska W; Box J; Legerton C; Nasonov E; Durez P; Aranda R; Pappu R; Delaet I; Teng J; Alten R
Arthritis Rheum; 2011 Oct; 63(10):2854-64. PubMed ID: 21618201
[TBL] [Abstract][Full Text] [Related]
14. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry.
Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Marcelli C; Bardin T; Pane I; Baron G; Mariette X
Ann Rheum Dis; 2012 Nov; 71(11):1815-9. PubMed ID: 22615458
[TBL] [Abstract][Full Text] [Related]
15. On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.
Bykerk VP; Burmester GR; Combe BG; Furst DE; Huizinga TWJ; Ahmad HA; Emery P
Rheumatol Int; 2018 Dec; 38(12):2225-2231. PubMed ID: 30341453
[TBL] [Abstract][Full Text] [Related]
16. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).
Mueller RB; Gengenbacher M; Richter S; Dudler J; Möller B; von Kempis J
Arthritis Res Ther; 2016 Apr; 18():88. PubMed ID: 27074795
[TBL] [Abstract][Full Text] [Related]
17. Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
Alten R; Mariette X; Lorenz HM; Nüßlein H; Galeazzi M; Navarro F; Chartier M; Heitzmann J; Poncet C; Rauch C; Le Bars M
Clin Rheumatol; 2019 May; 38(5):1413-1424. PubMed ID: 30790095
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.
Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Li T; Aranda R; Becker JC; Lin C; Cornet PL; Dougados M
Ann Rheum Dis; 2008 Aug; 67(8):1096-103. PubMed ID: 18055472
[TBL] [Abstract][Full Text] [Related]
19. Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks.
Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Asai S; Yoshioka Y; Takemoto T; Terabe K; Asai N; Ishiguro N
J Rheumatol; 2015 May; 42(5):786-93. PubMed ID: 25834204
[TBL] [Abstract][Full Text] [Related]
20. Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study.
Alemao E; Guo Z; Frits ML; Iannaccone CK; Shadick NA; Weinblatt ME
Semin Arthritis Rheum; 2018 Apr; 47(5):630-638. PubMed ID: 29241640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
